Rep. Porter Honored For Work on Budget

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

WASHINGTON--Representative John Edward Porter of Illinois has received an American Academy of Otolaryngology--Head and Neck Surgery, Inc. award for "superb legislative leadership for medical research."

WASHINGTON--Representative John Edward Porter of Illinois hasreceived an American Academy of Otolaryngology--Head and NeckSurgery, Inc. award for "superb legislative leadership formedical research."

Rep. Porter, in his first year as chairman of the House of Representative'sSubcommittee on Labor-HHS-Education and Other Related Agencies,succeeded in extricating medical research funding from the overallbudget battle, thus assuring continuation of medical researchat medical centers and universities throughout the country.

In presenting the award, Robert J. Ruben, MD, professor of pediatrics,Albert Einstein College of Medicine of the Yeshiva Universityand Montefiore Medical Center, New York City, said that Rep. Porter'sleadership "allows vital research work . . . to go forwarduninterrupted . . . not only in our field, but also in the fieldsof cancer, heart disease, and lung disease--indeed in all healthareas of profound interest to the American people, and peopleworldwide."

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content